Most patients with well-differentiated thyroid cancer (WDTC) are first treated by total thyroidectomy followed by remnant ablation (RA) with 131I. There are less data regarding the efficacy of recombinant human thyrotropin (rhTSH) for patients with WDTC at high risk of relapse than for low-risk patients. This study compared the efficacies of rhTSH and thyroid hormone withdrawal (THW) to prepare patients at high risk of relapse for RA.
Methods:
Post-thyroidectomy patients with WDTC and complete tumor resection (n = 275) were studied. They were at high risk of recurrence (tumor size >4 cm and/or extrathyroidal extension [pT3] and/or lymph node metastases), and they did not have antithyroglobulin (Tg) antibodies. Group A (n = 77) received 0.9 mg rhTSH for 2 consecutive days followed by RA on day 3. The remaining 198 patients (group B) were prepared by THW for 4 weeks. Patients in groups A and B received 3.7 or 5.5 GBq 131I.
Results:
The groups were similar in terms of gender, age, histology, TNM (tumor–node–metastases) stage, 131I activity, and frequency of metastases on post-therapy whole-body scanning (RxWBS). Among patients without metastases on RxWBS, RA was successful (stimulated Tg <1 ng/mL and negative diagnostic whole body scan and neck ultrasonography) in 56 of 70 patients in group A (80%) and in 135 of 169 patients in group B (79.9%). Among patients with Tg >1 ng/mL immediately before RA, the comparable success rates were 68.4% and 67.4%, respectively. Among patients with metastases on the first RxWBS, no uptake was observed on the RxWBS 1 year later in 5 of 7 patients in group A (71.4%) and in 17 of 29 patients in group B (58.6%). The rhTSH stimulated serum Tg was <1 ng/mL in 3 of 5 and in 12 of 17 patients with a second negative RxWBS in groups A and B, respectively. Persistent disease (stimulated Tg >1 ng/mL and RxWBS continuing to show ectopic uptake) occurred in 2 of 7 patients in group A (28.5%) and in 12 of 29 patients in group B (41.3%).
Conclusions:
rhTSH is as effective as THW for RA in patients with WDTC who are at a high risk of relapse.
Get full access to this article
View all access options for this article.
References
1.
PaciniF, SchlumbergerM, DralleH, EliseiR, SmitJW, WiersingaW. European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154:787–803.
Paz-FilhoGJ, GrafH. 2008. Recombinant human thyrotropin in the management of thyroid disorders. Expert Opin Biol Ther, 8:1721–1732.
4.
BiondiB, PulcranoM, PaganoL, LombardiG. 2009. Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics, 3:9–13.
5.
WartofskyL. 2009. Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision. Thyroid, 19:1139–1143.
6.
TuttleRM, LopezN, LeboeufR, MinkowitzSM, GrewalR, BrokhinM, OmryG, LarsonS. 2010. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid, 20:257–263.
7.
PilliT, BrianzoniE, CapoccettiF, CastagnaMG, FattoriS, PoggiuA, RossiG, FerrettiF, GuarinoE, BurroniL, VattimoA, CipriC, PaciniF. 2007. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab, 92:3542–3546.
8.
RosarioPW, BorgesMA, PurischS. 2008. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med, 49:1776–1782.
9.
RubinoC, de VathaireF, DottoriniME, HallP, SchvartzC, CouetteJE, DondonMG, AbbasMT, LangloisC, SchlumbergerM. 2003. Second primary malignancies in thyroid cancer patients. Br J Cancer, 89:1638–1644.
10.
RosarioPW, BarrosoAL, RezendeLL, PadrãoEL, BorgesMA, GuimarãesVC, PurischS. 2006. Testicular function alter radioiodine therapy in patients with thyroid cancer. Thyroid, 16:667–670.
11.
Souza-RosarioPW, Alvarenga-FagundesT, Villasboas FagundesAS, BarrosoAL, Lamego RezendeL, Lanza PadrãoE, GuimarãesVC, HortaAC, FrancoM, PurischS. 2005. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes, 113:331–333.
12.
RosarioPW, MaiaFF, BarrosoA, PadraoEL, RezendeL, PurischS. 2004. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol, 48:310–314.
13.
FrigoA, DardanoA, DaneseE, DavìMV, MoghettiP, ColatoC, FranciaG, BernardiF, TrainoC, MonzaniF, FerdeghiniM. 2009. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab, 94:3472–3476.
14.
BorgetI, RemyH, ChevalierJ, RicardM, AllynM, SchlumbergerM, De PouvourvilleG. 2008. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging, 35:1457–1463.
15.
PitoiaF, WardL, WohllkN, FrigugliettiC, TomimoriE, GaunaA, CamargoR, VaismanM, HarachR, MunizagaF, CoriglianoS, PretellE, NiepomniszczeH. 2009. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol, 53:884–887.
16.
MolinaroE, ViolaD, PassannantiP, AgateL, LippiF, CeccarelliC, PincheraA, EliseiR. 2009. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging, 53:490–502.
17.
RosarioPW, FagundesTA, RezendeLL, PadraoEL, BorgesMA, BarrosoAL. 2006. Assessing hypothyroidism in the preparation of patients with thyroid cancer: cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. Endocrinologist, 16:25–29.
18.
RosarioPW, FagundesTA, PurischS, PadraoEL, RezendeLL, BarrosoAL. 2005. Recombinant TSH in ablative therapy and follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol, 49:350–358.
19.
BarbaroD, BoniG, MeucciG, SimiU, LapiP, OrsiniP, PasquiniC, PiazzaF, CaciagliM, MarianiG. 2003. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab, 88:4110–4115.
20.
PaciniF, LadensonP, SchlumbergerM, DriedgerA, LusterM, KloosRT, ShermanS, HaugenB, CoroneC, MolinaroE, EliseiR, CeccarelliC, PincheraA, WahlRL, LeboulleuxS, RicardM, YooJ, BusaidyNL, DelpassandE, HanscheidH, FelbingerR, LassmannM, ReinersC. 2006. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab, 91:926–932.
21.
ZulewskiH, MüllerB, ExerP, MiserezAR, StaubJJ. 1997. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab, 82:771–776.
22.
RosarioPW, FariaS, BicalhoL, Gatti AlvesMF, BorgesMAR, PurischS, PadrãoEL, RezendeLL, BarrosoAL. 2005. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med, 24:1385–1389.
23.
RosarioPW, Tavares JúniorWC, BiscollaRP, PurischS, MacielRM. 2007. Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metabol, 51:593–600.
24.
RobbinsRJ, ChonJT, FleisherM, LarsonSM, TuttleRM. 2002. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?J Clin Endocrinol Metab, 87:3242–3247.
25.
PaciniF, MolinaroE, CastagnaMG, AgateL, EliseiR, CeccarelliC, LippiF, TaddeiD, GrassoL, PincheraA. 2003. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab, 88:3668–3673.
26.
do RosárioPW, BorgesMA, AlvesMF, PurischS, PadrãoEL, RezendeLL, BarrosoAL. 2006. Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy. Arq Bras Endocrinol Metabol, 50:909–913.
27.
BarbaroD, BoniG, MeucciG, SimiU, LapiP, OrsiniP, PasquiniC, TurcoA, MarianiG. 2006. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun, 27:627–632.
28.
ChianelliM, TodinoV, GrazianoF, PanunziC, PaceD, GuglielmiR, SignoreA, PapiniE. 2009. Low dose (2.0 GBq; 54 mCi) radioiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur J Endocrinol, 160:431–436.
29.
PaciniF, MolinaroE, CastagnaMG, LippiF, CeccarelliC, AgateL, EliseiR, PincheraA. 2002. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab, 87:4063–4068.
30.
TaïebD, SebagF, CherenkoM, Baumstarck-BarrauK, FortanierC, Farman-AraB, De MiccoC, VaillantJ, ThomasS, Conte-DevolxB, LoundouA, AuquierP, HenryJ, MundlerO. 2009. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol (Oxf), 71:115–123.
31.
EmmanouilidisN, MüllerJ, JägerM, KaadenS, HelfritzF, GünerZ, KespohlH, KnitschW, KnappWH, KlempnauerJ, ScheumannGF. 2009. Surgery and radio ablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human thyrotropin. Eur J Endocrinol, 161:763–769.
32.
PitoiaF, TamerE, SalvaiME, NiepomniszczeH. 2009. Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (Buenos Aires), 69:148–152.
33.
LeeJ, YunMJ, NamKH, ChungWY, SohEY, ParkCS. 2010. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid, 20:173–179.
34.
Tala JuryHP, CastagnaMG, FioravantiC, CipriC, BrianzoniE, PaciniF. 2010. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab, 95:230–237.
35.
BarbaroD, GrossoM, BoniG, LapiP, PasquiniC, OrsiniP, TurcoA, MeucciG, MarzolaMC, BertiP, MiccoliP, MarianiG, RubelloD. 2009. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging, 37:242–249.
36.
TuttleRM, BrokhinM, OmryG, MartorellaAJ, LarsonSM, GrewalRK, FleisherM, RobbinsRJ. 2008. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med, 49:764–770.
37.
HanscheidH, LassmannM, LusterM, ThomasSR, PaciniF, CeccarelliC, LadensonPW, WahlRL, SchlumbergerM, RicardM, DriedgerA, KloosRT, ShermanSI, HaugenBR, CarriereV, CoroneC, ReinersC. 2006. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med, 47:648–654.
